Pharmacokinetic study of voriconazole in immunocompromised adolescents aged 12 to <17 years
- Registry ID
- EUCTR2012-001151-39
- Source registry
- EUCTR
- Phase
- PHASE2
- Sponsor
- Pfizer Inc. 235 East 42nd Street, New York, NY 10017
- Last update
- 2026-08-16
Conditions
- Invasive fungal infections
Summary
To characterize the pharmacokinetics of voriconazole following an intravenous (IV) to oral switch regimen in immunocompromised adolescent subjects aged 12 to
<17 years who were at high risk for systemic fungal infection.
View on source registry